NCT03222401View on ClinicalTrials.gov

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

March 2, 2018

Study Completion Date

March 2, 2018

Conditions
Neisseria Gonorrhoeae
Interventions
DRUG

1 mg/kg single infusion of F598

1 mg/kg single infusion of F598

DRUG

3 mg/kg single infusion of F598

3 mg/kg single infusion of F598

DRUG

10 mg/kg single infusion of F598

10 mg/kg single infusion of F598

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors
All Listed Sponsors
lead

Alopexx Pharmaceuticals, LLC

INDUSTRY

NCT03222401 - Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males | Biotech Hunter | Biotech Hunter